We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2024 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (77)5/23/2024 6:04:05 PM
From: A.J. Mullen1 Recommendation

Recommended By

  Read Replies (1) of 97
What made Illumina was the purchase of Solexa - a British company that realized it was faster and cheaper to break up the DNA, analyze short lengths of DNA, and use computing to reassemble the full sequence. It was perfect, but it was good enough. Apparently there are parts of some genomes that have repetitions. Getting the number of repetitions correct is hard. Pacific Bio was the first to to long reads efficiently. Illumina agreed to buy them, but was forced to unwind the deal because of anti-trust concerns.

I owned Solexa. Foolishly, I cashed out at the buy-out and missed out on much of illumina's rise. ILMN was very well run. I bought back in at a later stage but have since sold again as I learned of other companies. ILMN now offers long read sequencing, and PACB short-reads, so they are competing acroos te spectrum. There is also a British company, led by some from Solexa, that's offering direct reads cheaply. Here's a fascinating animation of their technology -

ILMN's stock price has weathered the increase in interest rates better than its competitors. Its cash is greater than a billion dollars. It will still be around in five years. I'm less sure of PACB and Oxford Nanopore - the British company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext